01st week of 2009 patent applcation highlights part 43 |
Patent application number | Title | Published |
20090004207 | Methods and Compositions for Inhibiting Pathological Angiogenesis in the Eye - Disclosed herein are compositions and methods for inhibiting abnormal angiogenesis in the eye, particularly in the retina. The methods include administering to subject in need of treatment for pathological angiogenesis of the eye a pharmaceutically effective amount of an inhibitor of the receptor activity of the S1P2 receptor. Also included are compositions including an S1P2 receptor antagonist and an opthalmically acceptable excipient. | 2009-01-01 |
20090004208 | Method for designing hypoallergenic molecules for use in allergy desensitization with lessened chance of anaphylaxis, or as vaccines against allergic reactions - A unique method is disclosed for identifying and replacing surface amino acid residues of a protein allergen that reduces the antigenicity of its dominant IgE epitopes. The method is useful in the design of hypoallergenic molecules for use in allergy desensitization with lessened chance of anaphylaxis, or as vaccines against allergic reactions. | 2009-01-01 |
20090004209 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same - Provided are 4′-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 2009-01-01 |
20090004210 | Method for Preventing and Treating Alzheimer's Disease - The invention relates to the use of a compound comprising the following amino acid sequence X | 2009-01-01 |
20090004211 | METHOD FOR EFFECTING LOCALIZED, NON-SYSTEMIC AND SYSTEMIC, IMMUNOGENIC TREATMENT OF CANCER USING ERP57 TRANSLOCATION - Anthrocyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of ERP57 to the cell surface. Knock down of ERP57 inhibit the translocation of CRT, suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. In contrast, the blockade of ERP57 with blocking antibody had no effect on phagocytosis of anthracyclines-treated tumor cells by dendritic cells and their immunogenicity in mammals, such as mice. The anthracyclines-induced ERP57 translocation was mimicked by inhibition of the protein phosphatase1/GADD34 complex. Administration of recombinant ERP57 did not restore the immunogenicity of cell death elicited by etoposide and mitomycin C, or enhanced their antitumor effects in vivo, in contrast to the administration of recombinant CRT. These data identify the presence of ERP57 crucial for the translocation of CRT and to induce immunogenic cell death which will activate a anti-cancer immune responses. | 2009-01-01 |
20090004212 | Tumour vaccines for MUC1-positive carcinomas - Embodiments of the invention provide tumour vaccines, especially for activation of glycopeptide-specific cytotoxic T-cells by MHC class I pathway, comprising at least one peptide of 8-11 amino acids derived from the region SAPDTRPAPGST of the human epithelial mucin MUC1 containing the immunodominant PDTRPAP region and which is glycosylated on threonine of the immunodominant PDTRPAP region and start with SAP, APD or PDT at it's N-terminus. | 2009-01-01 |
20090004213 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY - The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof. | 2009-01-01 |
20090004214 | Cd4+ Survivin Epitopes and Uses Thereof - The invention concerns CD4+ T survivin epitopes and their vaccine and diagnostic uses. | 2009-01-01 |
20090004215 | Chimeric G protein based rabies vaccine - A novel chimeric protein of rabies virus designed to express a chimeric G protein at a high level in transgenic plants. A gene was also designed and chemically synthesised to encode the chimeric G protein and expressed at high level in plant tissue. The gene was expressed in transgenic tobacco plants to examine its therapeutic efficacy against infection by rabies virus. The chimeric G protein was enriched in plant membranes. The BalbC mice were immunised with the plant leaf expressed G-protein. Plant derived chimeric G protein elicited higher immune response as compared to the commercial vaccine. The mice displayed protective immunity when they were challenged with live virus. Chimeric G protein expressed at high level in plant leaves was demonstrated to function as a commercially valuable subunit vaccine against rabies virus infection. | 2009-01-01 |
20090004216 | Attenuated pestiviruses - This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E | 2009-01-01 |
20090004217 | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) - antigens that can be used to differentiate | 2009-01-01 |
20090004218 | Antigen-Carbohydrate Conjugates - The present invention generally relates to compositions comprising antigen-carbohydrate conjugates and methods of immune modulation featuring these reagents. | 2009-01-01 |
20090004219 | Novel Strain of Schizochytrium limacinum useful in the production of lipids and Extracellular Polysaccharides and process thereof - The present disclosure provides a novel mutant strain of | 2009-01-01 |
20090004220 | Compositions of Plant Carbohydrates as Dietary Supplements - Compositions of plant carbohydrates for dietary supplements and nutritional support for promotion and maintenance of good health. Defined nutritionally effective amounts of one to eleven essential saccharides, glyconutrients, are used in various inventive compositions as dietary supplements. The dietary composition herein can include phytonutrients, vitamins, minerals, herbal extracts, and other non-toxic nutrients. The glyconutritional dietary supplement herein provides essential saccharides which are the building blocks of glycoproteins. These compositions, when administered orally or topically, have been found to improve the well being of mammals suffering from a variety of disorders. | 2009-01-01 |
20090004221 | Mutant Porcine Reproductive and Respiratory Syndrome Virus - The present invention provides a genetically modified PRRS virus which has been modified such that the conserved cysteine in the E protein has been deleted or changed to a non-cysteine residue and polynucleotides that encode it. Vaccines comprising the genetically modified virus and polynucleotides are also provided. | 2009-01-01 |
20090004222 | Influenza Vaccination - Influenza viruses have traditionally been administered by intramuscular injection. The invention is based on the idea of using alternative routes of delivery for influenza vaccines, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naive to influenza virus (i.e. have not previously mounted an immune response to an influenza virus), which means that it is advantageous for immunising young children. | 2009-01-01 |
20090004223 | Capsule composition for use as immunogen against campylobacter jejuni - An immunogenic composition, and method of using the composition to elicit an immune response to | 2009-01-01 |
20090004224 | ACTIVATABLE CLOSTRIDIAL TOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 2009-01-01 |
20090004225 | TOXIN COMPOUNDS WITH ENHANCED MEMBRANE TRANSLOCATION CHARACTERISTICS - The present invention relates to a compound comprising a toxin linked to a translocator. Non-limiting examples of toxins of the present invention are botulinum toxin, butyricum toxin, tetani toxins and the light chains thereof. In some embodiments, the translocator of the present invention comprises a protein transduction domain. | 2009-01-01 |
20090004226 | Fusion proteins of mycobacterium tuberculosis - The present invention relates to compositions and fusion proteins containing at least two | 2009-01-01 |
20090004227 | Peroral Vaccine Carrier System - The present invention provides a system in which a recombinant plant expressing a target peptide is orally administered to thereby achieve exertion of the function of the peptide, along with the genetically recombinant plant, and the present invention relates to a carrier system for oral administration of a target peptide by oral administration of a plant (potato) that expresses a target peptide by expressing for example a fused gene obtained by fusing the LRE1 gene coding for the immunogenic peptide LRE1 derived from the | 2009-01-01 |
20090004228 | BORON COMPOUND-LAYERED DOUBLE HYDROXIDE NANOHYBRID, METHOD OF PREPARING THE BORON COMPOUND-LDH NANOHYBRID, AND PHARMACEUTICAL COMPOSITION COMPRISING THE BORON COMPOUND-LDH NANOHYBRID - Provided are a boron compound-layered double hydroxide (LDH) nanohybrid in which a boron compound for boron neutron capture therapy is intercalated in between layers of LDH, a method of preparing the boron compound-LDH nanohybrid, and a pharmaceutical composition including the boron compound-LDH nanohybrid, which can be used in boron neutron capture therapy. | 2009-01-01 |
20090004229 | RUPTURING CONTROLLED RELEASE DEVICE COMPRISING A SUBCOAT - The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane. | 2009-01-01 |
20090004230 | Thermosetting Neutralized Chitosan Composition Forming a Hydrogel, Lyophilizate, and Processes for Producing the Same - The aqueous thermosetting neutralized chitosan composition, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C., comprises 0.1 to 5.0 w/w %, based on the total composition, of a reacetylated chitosan having a molecular weight of not smaller than 100 kDa and a deacetylation degree of 40 to 70%, neutralized with an hydroxylated base, and 1 to 30 w/w %, based on the total composition, of a complexing agent selected from polyoses and polyols derived from polyoses. Said composition is useful for the preparation of an injectable formulation. | 2009-01-01 |
20090004231 | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring - Nanomaterials fabricated to pharmaceutical dosage forms used to monitor quality of the drug product enclosed therein are disclosed. The nanomaterials are useful to provide a plurality of quality analysis to the dosage form. Consequently, the nanomaterials provide a means to perform quality testing on a continuous basis throughout the supply chain, including the cold chain whereby manufacturers and distributors can achieve greater product integrity and longer shelf life and ultimately minimize cost. The end user benefits in obtaining the highest quality drugs at the time of need. | 2009-01-01 |
20090004232 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF - Physically stable pharmaceutical/cosmetic compositions contain at least one hydrophilic phase, at least one lipophilic phase and at least one active principle, e.g., at least one steroidal anti-inflammatory agent, anti-fungal agent, anti-parasitic agent, nuclear receptor modulator and/or sex steroid, said at least one active principle being present in dissolved state in each of these phases; these are formulated via characteristic multi-step methodology. | 2009-01-01 |
20090004233 | MICROENCAPSULATING COMPOSITIONS, METHODS OF MAKING, METHODS OF USING AND PRODUCTS THEREOF - Products comprising core materials, such as polyunsaturated fatty acids, encapsulated by an encapsulant formed from hydrolyzed protein having a degree of protein hydrolysis of between about 1% and about 15%, and from caramelization products, are disclosed. Methods of making the same and of making the encapsulant are also provided. | 2009-01-01 |
20090004234 | DOSING DEVICE - A dosing device for dosing active substances in washing or cleaning processes, encompassing a container and a) a first active substance composition, present in said container, that contains at least one carrier material and at least one active substance; and b) a second active substance composition, present in said container, that likewise contains at least one carrier material and at least one active substance, but differs in terms of at least one of its ingredients from the first active substance composition, wherein the carrier material in at least one active substance composition is water-insoluble, is suitable for the release of different active substances and is notable for an improved release profile as compared with conventional dosing devices. | 2009-01-01 |
20090004235 | Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals - A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed | 2009-01-01 |
20090004236 | PESTICIDAL EAR TAG - Pesticidal compositions and articles providing topical application of a mixture of (1) a macrolide of the avermectin/milbemycin class, such as, but not limited to ivermectin, abamectin, or milbemectin, and (2) a synergist of the aryl aliphatic ether-class, such as, but not limited to piperonyl butoxide, present in (3) a weight ratio of synergist:macrolide that is great than 1:1. The compositions and articles demonstrate efficacy, even in point-of-contact applications, against various pests of domestic animals, such as, but not limited to arthropod ectoparasites including horn flies and buffalo flies. Methods are provided in which compositions can be employed as pour-ons, spot-ons, dusts, or sprays for direct topical application to the domestic animal; or in which articles comprising a polymer resin base, such as an ear tag, from which the active ingredients of the composition can be released, are affixed to the animal to provide long-term delivery. | 2009-01-01 |
20090004237 | B7-Like Molecules and Uses Thereof - The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides. | 2009-01-01 |
20090004238 | IMPLANTATION OF ENCAPSULATED BIOLOGICAL MATERIALS FOR TREATING DISEASES - Methods of applying biocompatible coating materials around biological materials using photopolymerization while maintaining the pre-encapsulation status of the biological materials are disclosed. The coatings can be placed directly onto the surface of the biological materials or onto the surface of other coating materials that hold the biological materials. The components of the polymerization reactions that produce the coatings can include natural and synthetic polymers, macromers, accelerants, cocatalysts, photoinitiators, and radiation. Methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site are also disclosed. The coating materials can be manipulated to provide different degrees of biocompatibility, protein diffusivity characteristics, strength, and biodegradability to optimize the delivery of biological materials from the encapsulated implant to the host recipient while protecting the encapsulated biological materials from destruction by the host inflammatory and immune protective mechanisms without requiring long-term anti-inflammatory or anti-immune treatment of the host. | 2009-01-01 |
20090004239 | Dural repair material - Multilayer structures including a porous layer and a non-porous layer having a reinforcement member are useful as dural repair materials. | 2009-01-01 |
20090004240 | IMPLANTS WITH A PHOSPHAZENE-CONTAINING COATING - The present disclosure relates to implants with a biocompatible coating having antithrombogenic properties and which also contains a pharmacologically active agent, as well as a process for their production. | 2009-01-01 |
20090004241 | POLYMER NANOFILM COATINGS - Disclosed herein are nanofilm coatings for implantable medical devices comprising a diblock or triblock copolymer (PEO-PMMA or PMOXA-PDMS-PMOXA, respectively). Such nanofilms, may be used, for example, as amphiphilic supports for therapeutic agents. These materials are conducive towards the formation of active substrates for a suite of biological and medical applications. | 2009-01-01 |
20090004242 | Coatings and Biomedical Implants Formed From Keratin Biomaterials - Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof. | 2009-01-01 |
20090004243 | Biodegradable triblock copolymers for implantable devices - The present invention is directed to polymeric materials made of biodegradable, bioabsorbable triblock copolymers and implantable devices (e.g., drug-delivery stents) containing such polymeric materials. The polymeric materials may also contain at least one therapeutic substance. The polymeric materials are formulated so as to improve the mechanical and adhesion properties, degradation, biocompatibility and drug permeability of such materials and, thus, implantable devices formed of such materials. | 2009-01-01 |
20090004244 | Iris design as a drug depot for zonal drug delivery by contact lens - A contact lens providing zonal drug delivery includes a lens body having an optical axis and an opaque simulated iris pattern applied to the lens body, about the optical axis, with the pattern including an ophthalmic drug. | 2009-01-01 |
20090004245 | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens - A drug delivery device includes a contact lens along with a drug delivery zone disposed above an applied axis of the lens. A colored layer is disposed over the drug delivery zone in order to mark a color of the drug delivery zone. | 2009-01-01 |
20090004246 | INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE DELIVERY OF MACROMOLECULES AND WATER-SOLUBLE DRUGS - An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use. | 2009-01-01 |
20090004247 | Novel substance derived from basidiomycetes culture, method for producing it and its use - A novel substance that has the physiological activity of the aglycone of isoflavones and the physiological activity of the culture of the basidiomycetes with the physiological activities being synergistically enhanced, obtained by cultivating a basidiomycetes having a β-glucosidase activity in a medium containing an isoflavone, a method for producing it, and food, feedstuff and medicine containing it. | 2009-01-01 |
20090004248 | DUAL PORTION DOSAGE LOZENGE FORM - The present invention relates to a dosage form including both a disintegrative tablet portion and a hard candy portion, wherein: (i) the disintegrative tablet portion comprises at least one pharmaceutically active agent, and (ii) the hard candy portion covers at least 20% of the surface of the disintegrative tablet portion, and wherein the disintegration time of the hard candy portion is at least ten times longer than the disintegration time of the disintegrative tablet portion. | 2009-01-01 |
20090004249 | DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE - This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use. | 2009-01-01 |
20090004250 | DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE - This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use. | 2009-01-01 |
20090004251 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins and/or the novel lactic acid-producing strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 2009-01-01 |
20090004252 | Skin Coating Composition and Uses Thereof - The present invention relates to a composition for coating the skin wherein the composition forms a water-proof flexible film on the skin. Preferably, the flexible film is durable and is capable of remaining adhered to the skin for 1 to 3 days. The composition may include (i) one or more pigments and/or dyes, or (ii) one or more sunscreen agents or (iii) one or more therapeutic agents for preventing or treating disorders of the skin. The coating composition comprises resin and flexibilizer (platicizer). Any suitable type of natural or synthetic resin may be used, preferably the resin is shellac or other natural gum derivative. A suitable flexiblizer is an animal, vegetable, mineral or synthetic oil, preferably castor oil, pine oil, rosehip oil or soya bean oil or mixture thereof. The composition optionally includes a diluent such as ethanol, a cellulosic preparation such as ethyl cellulose, an anti-agglomerating or dispersing agent and a thickener. The composition may be in the form of a paste, cream, gel, liquid or aerosol and may be used as a bandage or artificial skin. | 2009-01-01 |
20090004253 | Composite device for the repair or regeneration of tissue - The present invention is directed to composite devices comprising a tissue-engineering scaffold and an anionic polysaccharide/structural protein coating. The composite devices are useful for the reparation and regeneration of tissue, particularly in the treatment of chronic wounds. | 2009-01-01 |
20090004254 | FILM COMPRISING ACTIVE DRUGS - The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed. | 2009-01-01 |
20090004255 | Adhesive patch for external use with improved cohesive force and sustained-release characteristics - The amount of penetration into the skin in adhesive patches generally tends to show a certain peak and trough. An adhesive patch is provided in which the drug shows satisfactory penetrability because of a polymer proportion and drug penetration is constant over a certain period. The adhesive patch for external use has a pressure-sensitive adhesive layer containing a drug. It is characterized in that the pressure-sensitive adhesive layer comprises: polyvinylpyrrolidone and/or a copolymer of monomers including vinylpyrrolidone as the main ingredient; and a (meth)acrylic ester copolymer having a basic nitrogen atom and/or cationic nitrogen atom. | 2009-01-01 |
20090004256 | Lowly irritative adhesive patch - An adhesive patch for external use which is significantly inhibited from causing a rash, is less irritative to the skin, and sufficiently retains adhesion to the skin. The adhesive patch is characterized by employing a pressure-sensitive adhesive base into which a sucrose fatty acid ester has been incorporated. It does not exert physical influences on the skin, such as stresses imposed on the skin during wear and upon peeling, while sufficiently retaining adhesion to the skin. It is significantly inhibited from causing a rash, and the skin irritation thereof has been minimized. This adhesive patch for external use has ideal, lowly irritative properties which have been impossible to any conventional adhesive patch for external use. | 2009-01-01 |
20090004257 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF - A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. | 2009-01-01 |
20090004258 | Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field - Thermosensitive liposomes encapsulating paramagnetic iron oxide nanoparticles are used as a drug controlled release system. Paramagnetic iron oxide nanoparticles are used to generate heat by applying alternative magnetic field to cause leakage of drugs in the liposomes. | 2009-01-01 |
20090004259 | METHODS OF PREPARING A THERAPEUTIC FORMULATION COMPRISING GALECTIN-INDUCED TOLEROGENIC DENDRITIC CELLS - In spite of their pivotal role in orchestrating immunity, dendritic cells (DCs) may be licensed by immunosuppressive signals to become tolerogenic. Here we show that ligation of cell surface glyco-receptors by Galectin-1, an endogenous glycan-binding protein, can drive the differentiation of regulatory DCs with tolerogenic potential in vivo. Galectin-1-differentiated DCs acquired a tolerogenic phenotype characterized by IL-27-dependent, STAT3-mediated and CD45RB | 2009-01-01 |
20090004260 | MEDICAMENT COMPRISING HGF GENE - The present invention relates to a method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering to the area affected by the insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby the HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells. | 2009-01-01 |
20090004261 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A PYRAZOLE-3-CARBOXAMIDE DERIVATIVE - this invention discloses and claims a pharmaceutical composition in liquid or semi-liquid form, which is self-emulsifying or self-microemulsifying in aqueous medium, for the oral administration of a pyrazole-3-carboxamide derivative, in which said derivative is dissolved in an amphiphilic mixture containing one or more lipid solvents and a nonionic hydrophilic surfactant. | 2009-01-01 |
20090004262 | Nanoparticulate formulations and methods for the making and use therof - The present invention is directed to size-stabilized drug nanoparticulate compositions and methods of preparation thereof. | 2009-01-01 |
20090004263 | Modified release preparations containing oxcarbazepine and derivatives thereof - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 2009-01-01 |
20090004264 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES - This invention relates to methods of treatment of inflammatory bowel disease, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the methods of the invention are disclosed. | 2009-01-01 |
20090004265 | Prevention and Treatment of Thromboembolic Disorders - The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less. | 2009-01-01 |
20090004266 | Nanoparticles for protein drug delivery - The invention discloses a chewable composition for oral delivery of bioactive agents having nanoparticles that are composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 2009-01-01 |
20090004267 | Dosage Form with Impeded Abuse - A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm. | 2009-01-01 |
20090004268 | Methods and Compositions for Treatment of an Interstitial Lung Disease - Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof. | 2009-01-01 |
20090004269 | Pharmaceutical Composition Comprising a Proton Pump Inhibitor and a Protein Component - The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H | 2009-01-01 |
20090004270 | METHOD OF USING GUAVA EXTRACT - A method of using guava extract is disclosed that includes administering guava extract to a mammal to inhibit, prevent or alleviate at least one of a headache, nausea, dry mouth, lack of appetite, shakiness, and fatigue. A composition is also disclosed that includes a pharmaceutically acceptable carrier and guava extract. | 2009-01-01 |
20090004271 | Morselized foam for wound treatment - A wound treatment material comprising morselized foam is described. The morselized foam comprises a biocompatible, biodegradeable polymer. Methods for wound treatment and/or repair and/or regeneration of tissue using morselized foam are disclosed. | 2009-01-01 |
20090004272 | Polymeric devices for controlled release of active agents - Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject. | 2009-01-01 |
20090004273 | Polymeric device for controlled release of active agents - Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject. | 2009-01-01 |
20090004274 | Hydrogen Bonded Hydrogels - The present invention relates to new hydrogel materials using water gellants that are comprised by hydrophilic polymers to which hydrogen bonding units are covalently attached. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical performance and functionality and are especially suitable for cosmetic and biomedical applications. | 2009-01-01 |
20090004275 | Composition for Delivery of an Active Agent - A composition for oromucosal delivery of a biologically active agent, which composition releases the active agent within 5 minutes when applied to an oramucosal surface in use, comprises a biologically active agent and a matrix-former. The biologically active agent may be present as an ion pair complex. | 2009-01-01 |
20090004276 | Novel injectable chitosan mixtures forming hydrogels - A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions. | 2009-01-01 |
20090004277 | Nanoparticle dispersion containing lactam compound - Disclosed is a nanoparticle dispersion comprising nanoparticles dispersed in an aqueous medium in the presence of at least one stabilizer. The nanoparticles comprise at least lactam compound of formula I: | 2009-01-01 |
20090004278 | Enzymatically Crosslinked Protein Nanoparticles - It is an object of the present invention to provide highly safe nanoparticles made from highly biocompatible materials without the use of a surfactant or synthetic polymer. The present invention provides a protein nanoparticle which is obtained by enzymatic crosslinking during and/or after the formation of protein nanoparticle. | 2009-01-01 |
20090004279 | Method For Improvement Of Tolerance For Therapeutically Effective Agents Delivered By Inhalation - A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition. | 2009-01-01 |
20090004280 | KIT FOR CARING FOR THE SKIN INTENDED TO SOFTEN CUTANEOUS SIGNS OF AGEING - A kit for skin care intended to soften cutaneous signs of ageing, contains in separate packagings, a microdermabrasion composition, a peeling composition, a soothing composition and an anti-ageing composition. | 2009-01-01 |
20090004281 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM - The present invention relates to a multiparticulate osmotic delivery system. The system is a modified release composition suitable for oral administration. The composition includes a core that includes at least one drug in combination with at least one pharmaceutically acceptable excipient. The composition further includes an osmotic subcoat surrounding the core, and a modified release overcoat surrounding the osmotic subcoated core. | 2009-01-01 |
20090004282 | Method of Particle Formation - A method of co-formulating two or more pharmaceutically active compounds into a particulate product including contacting a dense, supercritical or near-critical fluid With a suspension of a first active compound in a medium that is miscible with the dense fluid and a solution of a second active compound in a solvent that is miscible with the dense fluid. The product may be the first active agent coated with the second active agent. The method may use coaxial nozzles for the fluid, media or solvents. The method may be applied to production of dry powders for inhalation including beta-agonists and corticosteroids. Apparatus for use in the method comprising means for streams of solvents, media and dense fluids to enter a precipitation chamber at substantially the same point and means for collection of particles under gravity in one or more collection chambers. | 2009-01-01 |
20090004283 | Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-Co-Glycolide Polymers - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs). | 2009-01-01 |
20090004284 | Controlled release tamsulosin hydrochloride formulation - The present invention relates to a controlled release pellet of tamsulosin and its pharmaceutically acceptable salts that comprise an inert starting seed or core. | 2009-01-01 |
20090004285 | Stable non-disintegrating dosage forms and method of making same - The present invention is a stable, non-disintegrable dosage form which combines the benefits of a microencapsulated substrate with the convenience of direct compression. The present invention is also directed to methods for producing directly compressed microencapsulated dosage forms to provide modified release and dosage form stability. The dosage unit can have a high active load. | 2009-01-01 |
20090004286 | COMPOSITIONS FOR ACHIEVING A THERAPEUTIC EFFECT IN AN ANATOMICAL STRUCTURE AND METHODS OF USING THE SAME - Compositions and methods of using the compositions to achieve a therapeutic effect are provided. | 2009-01-01 |
20090004287 | Disinfectant formulations containing quaternary ammonium compounds and hydrogen peroxide - Disinfectant compositions having at least one biocidal quaternary ammonium carbonate and/or bicarbonate and hydrogen peroxide. A method for killing or inhibiting the growth of microorganisms, algae and fungi involves applying the disinfectant compositions. Methods involving inhibiting the decomposition of aqueous hydrogen peroxide solutions and involving inhibiting the corrosive action of aqueous hydrogen peroxide on metals. | 2009-01-01 |
20090004288 | STABILIZED OPHTHALMIC SOLUTIONS - The present invention relates to stabilized ophthalmic solutions comprising at least one peroxide. In one embodiment, the present invention relates to an ophthalmic solution comprising a pH between about 6 and about 8 and about 50 to about 1000 ppm hydrogen peroxide and about 0.005 wt % (50 ppm) to about 0.05 wt % (500 ppm) at least one salt of diethylenetriamine pentaacetic acid selected from the group consisting of calcium salts of diethylenetriamine pentaacetic acid, zinc salts of diethylenetriamine pentaacetic acid and mixed calcium/zinc salts of diethylenetriamine pentaacetic acid. | 2009-01-01 |
20090004289 | Method of disinfecting and providing residual kill at a surface - The present invention is drawn to disinfectant systems and methods which can be used to produce a disinfectant solution. The system can include a first liquid composition and a second liquid composition. The first liquid composition comprises from 0.0005 ppm to 100,000 ppm by weight of a transition metal or alloy and an alcohol, and the second liquid composition comprises water and a peroxygen compound. The first and second liquid compositions are formulated to be combined so as to yield a resultant disinfectant solution. The disinfectant solution can be used to disinfect a variety of surfaces and even liquid compositions. | 2009-01-01 |
20090004290 | RED YEAST RICE COMPOUND FOR CANCER CHEMOPREVENTION - The invention concerns a composition containing red yeast rice and other components, as a chemopreventative agent to reduce the risk of cancer. | 2009-01-01 |
20090004291 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIA - The present invention relates to a method of treating, preventing, or delaying the onset of Alzheimer's disease and/or dementia in mammals. More particularly, the invention relates to method of administration of compositions containing defined chemical species useful for treating, preventing, or delaying the onset of Alzheimer's disease and/or dementia in mammals. In some embodiments, a composition used in connection with such methods comprises one or more of 1) thyroid hormone and 2) cyclo(His-Pro) and a zinc salt. Such compositions may also be used to treat metabolic syndrome and cerebrovascular diseases. | 2009-01-01 |
20090004293 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers - Compounds and related methods for synthesis, and the use of compounds and combination therapies for the treatment of cancer and modulation of apoptosis in cells are disclosed. Particularly disclosed are phosphonate esters. Compounds, methods of making the compounds, medicaments and method of manufacture of medicaments and therapeutic methods with applications against cancer including breast cancer, melanoma, colon cancer, leukemia and lymphoma, and other cancer cells are described. | 2009-01-01 |
20090004294 | PERSONAL LUBRICANT FORMULATIONS COMPRISING COLLOIDAL METALS AND METHODS OF USE - Lubricant compositions and methods are disclosed for aiding and enhancing massage or sexual activity, treating and preventing sexually transmitted diseases, and preventing pregnancy by administering a colloidal metal containing composition. Colloidal metal containing compositions that include metal flakes, sperm-function inhibitors, antimicrobial agents, analgesics, plant extracts, anti-oxidizing agents, and anti-inflammatory agents are also provided and may advantageously be used to in the methods of the invention. | 2009-01-01 |
20090004295 | USE OF A CHEMICALLY-STABILIZED CHLORITE SOLUTION FOR INHIBITING AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - Methods of using a stabilized chlorite solution to inhibit antigen-specific immune responses are disclosed. The stabilized chlorite solution, when administered to a mammal in need thereof, can prevent the presentation of antigens by antigen presenting cells. The stabilized chlorite solution therefore is useful in treating, inter alia, auto-immune diseases, treating diseases caused by an inappropriate immune response, treating lymphoproliferative disease and in inhibiting rejection in transplant patients. | 2009-01-01 |
20090004296 | Antiseptic Compositions and Methods of Using Same - A novel antiseptic composition comprising an antiseptic in a carrier composition comprising nanostructures and a liquid and methods of use thereof are provided. | 2009-01-01 |
20090004297 | Calcium carbonate compositions for preventing or treating hyperphosphatemia - Compositions and methods for inhibiting gastrointestinal absorption of phosphate in a subject are provided. Such compositions are composed of enteric-coated, sustained-release calcium carbonate, which find application in the prevention or treatment of hyperphosphatemia. | 2009-01-01 |
20090004298 | Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing - The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. | 2009-01-01 |
20090004299 | Methods for Inhibiting a Decline in Learning and/or Memory in Animals - A method for inhibiting a decline in learning and/or memory in an animal comprising maintaining the animal on an antioxidant-fortified diet for a period of at least about 3 years. The diet comprises at least one antioxidant in a total antioxidant amount effective to achieve such inhibition. Suitable antioxidants include vitamin E, vitamin C, α-lipoic acid and antioxidant-containing plant meals. The methods are particularly useful for young adult canines such as dogs. | 2009-01-01 |
20090004300 | Method and Composition for Enhancing Fertility - The invention relates to a method and composition for enhancing fertility, including the steps of preparing a formula by mixing between approximately 2 grams and approximately 10 grams of each of the following components: Radix Ginseng Rubra, Semen Ziziphi Spinosae, Radix Angelicae Sinensis, Radix Astragali, Rhizoma Atractylodis, Screrotium Poriae Cocos, Radix Glycyrrhizae Uralensis, Semen Persicae, Flos Carthami Tinctorii, Folium Artemisiae, Cornu Cervi Parvum, and combinations thereof; and preparing a second formula by mixing between approximately 2 grams and approximately 10 grams of each of the following components: Radix Ginseng Rubra, Rhizoma Atractylodis, Folium Perillae, Radix Scutellariae Baicalensis, Radix Glycyrrhizae Uralensis, Semen Cuscutae, Radix Astragali, Radix Dipsaci, and combinations thereof. | 2009-01-01 |
20090004301 | Method of treating dyshidrosis(pompholyx) and related dry skin disorders - This invention discloses a method of use for a topical herbal formulation alone or in combination with oral administration of niacin (preferably a flush preparation) to prevent and/or treat dyshidrosis (pompholyx) and related skin diseases. The formulation may also be used to treat contact dermatitis, eczema, palmoplantar pustulosis and skin infections incurred by invasive pathogens such as mold, fungus and bacteria. The formulation is comprised of plant extracts and niacin, that when combined yield an effective multi-faceted pharmaceutical approach to treating dry skin disorders. The active ingredients within the formula include a combination of dry, aqueous, acid and alcohol extracts of black walnut hull ( | 2009-01-01 |
20090004302 | Methods and Therapeutic Compositions Comprising Plant Extracts for the Treatment of Cancer - A method of treating cancer by targeting two proteases, MMP-9 and cathepsin B is provided. Therapeutic compositions comprising one or more plant extracts that inhibit MMP-9 and/or cathepsin B, which are capable of inhibiting neoplastic and/or endothelial cell migration, tumour growth, tumour-induced angiogenesis and/or metastasis are also provided. The therapeutic compositions of the invention can be used in the treatment of cancer, and, methods of inhibiting tumour growth, tumour metastasis, and/or tumour-induced angiogenesis using the therapeutic compositions alone or in combination with an anti-cancer agent are, therefore, also provided. | 2009-01-01 |
20090004303 | Perfume Compositions - Perfume ingredients and essential oils in synergistic combinations improve well-being by down-regulating arousal. This could lead to enhanced quality of life and reduced stress. The perfume compositions of the invention comprise one or more materials from each of the following groups: Group A: the essential oils lavender, lavandin, bergamot, chamomile, clary sage; Group B: 2-phenoxyethanol, 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone, benzophenone, cyclopentadecanolide, alpha-ionone, beta-ionone, para-methylacetophenone, [4-isopropylcyclohexyl]methanol. The ratio of the weight percentage based on the composition of group A materials to Group B materials lies within the range 1:9 to 9:1. | 2009-01-01 |
20090004304 | COMPOSITION COMPRISING BIOACTIVE SUBSTANCE - The present invention provides a powder superior in water-dispersibility/solubility, workability and tabletability, which contains an oil component containing a bioactive substance, a water-soluble polymer, a saccharide other than polysaccharides and a surfactant, at a particular ratio. The powder can be utilized for food, food with nutrient function claims, food for specified health uses, nutritional supplement, nutritional product, animal drug, drinks, feed, pharmaceutical product, quasi-drug, cosmetic and the like. | 2009-01-01 |
20090004305 | Antimicrobial and antiviral composition - An antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares includes an antiseptic solution in combination with | 2009-01-01 |
20090004306 | Composition for treatment of diabetes and maintaining healthy blood glucose levels - A medicinal composition is presented for the treatment of diabetes in human patients. The medicinal composition of the invention includes hypoglycemic properties that allows some patients to discontinue use of anti-diabetic pharmaceuticals in favor of this medicinal composition. The medicinal composition of the invention allows human patients to maintain healthy blood glucose levels. | 2009-01-01 |
20090004307 | Aloe Vera Extract, Method of Producing Aloe Vera Extract, and Hyperglycemia Improving Agent - The present invention provides: an | 2009-01-01 |